Expert Review of Clinical Pharmacology最新文献

Golimumab retention in patients with psoriatic arthritis and axial spondyloarthritis: evidence from up to a decade of follow-up. Golimumab在银屑病关节炎和轴性脊柱炎患者中的保留：长达十年的随访证据

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2025-05-19 DOI: 10.1080/17512433.2025.2508960

Paula Alvarez, Arancha Gómez-Cosme, Pablo González Del Pozo, Norma Calleja, Mercedes Alperi, Rubén Queiro

{"title":"Golimumab retention in patients with psoriatic arthritis and axial spondyloarthritis: evidence from up to a decade of follow-up.","authors":"Paula Alvarez, Arancha Gómez-Cosme, Pablo González Del Pozo, Norma Calleja, Mercedes Alperi, Rubén Queiro","doi":"10.1080/17512433.2025.2508960","DOIUrl":"10.1080/17512433.2025.2508960","url":null,"abstract":"Background: While there are relatively large number of studies on the retention of biologics in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), very long-term retention studies are scarce.Research design and methods: Retrospective longitudinal study including patients with up to a decade of follow-up. Survival rate was analyzed using Kaplan-Meier curves and drug discontinuation-associated factors using multivariate Cox regression. Hazard Ratio (HR) was used as a measure of the association.Results: Ninety PsA patients and 93 with axSpA were included. Retention rate ranged from 64% at year 1 to 25% at year 11 in PsA, whereas in axSpA, these figures ranged from 68% at year 1 to 34% at year 12. The rate of any event leading to drug discontinuation was 20.9/100PYs and 14.8/100PYs in PsA and axSpA, respectively. Age at arthritis onset (HR 0.93, 95%CI: 0.87-0.99, p = 0.048) and psoriasis duration (HR 1.08, 95%CI: 1.0-1.2, p = 0.036) were linked to drug discontinuation in PsA. In axSpA, retention rate was significantly higher in men compared to women (long-rank p = 0.037).Conclusion: In this real-world study, a non-negligible retention of GOL is observed. The two diseases differ in the factors that appear to determine drug persistence.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1-10"},"PeriodicalIF":3.6,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Physiologically-based pharmacokinetic modeling to predict the exposure and provide dosage regimens of adalimumab in patients with juvenile idiopathic arthritis. 基于生理的药代动力学模型预测阿达木单抗在幼年特发性关节炎患者中的暴露并提供剂量方案。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2025-05-12 DOI: 10.1080/17512433.2025.2502366

Ya-Xin Liu, Li-Ying Gong, Jin-Long Liu, Qi Pei, Yun Kuang, Guo-Ping Yang

{"title":"Physiologically-based pharmacokinetic modeling to predict the exposure and provide dosage regimens of adalimumab in patients with juvenile idiopathic arthritis.","authors":"Ya-Xin Liu, Li-Ying Gong, Jin-Long Liu, Qi Pei, Yun Kuang, Guo-Ping Yang","doi":"10.1080/17512433.2025.2502366","DOIUrl":"https://doi.org/10.1080/17512433.2025.2502366","url":null,"abstract":"Background: Adalimumab has been approved for treating juvenile idiopathic arthritis (JIA). This study aimed to develop a physiologically-based pharmacokinetic (PBPK) model for adalimumab in JIA patients to optimize personalized treatment.Methods: A comprehensive literature search identified 13 clinical studies as the dataset for constructing and validating a PBPK model of adalimumab. Initially, a PBPK model for adalimumab in adults was constructed using PK-Sim and Mobi software. Subsequently, virtual pediatric populations were created by incorporating age-dependent parameters from the PK-Sim database, extending the model to JIA patients. Finally, based on the developed PBPK model for adalimumab in JIA patients, dosing regimens were evaluated for different age groups.Results: This study successfully developed and validated a PBPK model for adalimumab in both adult and pediatric populations. The model for adults accurately predicted 92.90% of the concentrations within 0.5-2 times the observed values, while the pediatric model predicted 90.62% of the concentrations within 0.5-2-fold range. For pediatric patients with JIA, age- and weight-based dosing is recommended to achieve trough concentrations comparable to those in adults.Conclusion: A PBPK model for adalimumab in pediatric patients with JIA was developed, providing a basis for personalized dosing regimens in this population.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1-8"},"PeriodicalIF":3.6,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Practical challenges and considerations in adopting biosimilars in oncology clinical practice within a large healthcare system. 实际的挑战和考虑采用生物仿制药在肿瘤临床实践中的大型医疗保健系统。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2025-04-30 DOI: 10.1080/17512433.2025.2492063

Mansoor A Khan, Laila Carolina Abu Esba, Consuela Cheriece Yousef, Mohammed Alharbi, Hind Modaimegh, Hend Metwali, Hana Abdulkarim, Majed Alshamrani, Mohamad Aseeri, Mubarak Almansour, Ahmad Alsaeed, Mousa Alahmari, Anjum Naeem Ansari, Meteb Alfoheidi, Ahmed Absi, Turki Alfayea, Eman Youssif, Ayman Alhejazi, Mansour Alodhaib

{"title":"Practical challenges and considerations in adopting biosimilars in oncology clinical practice within a large healthcare system.","authors":"Mansoor A Khan, Laila Carolina Abu Esba, Consuela Cheriece Yousef, Mohammed Alharbi, Hind Modaimegh, Hend Metwali, Hana Abdulkarim, Majed Alshamrani, Mohamad Aseeri, Mubarak Almansour, Ahmad Alsaeed, Mousa Alahmari, Anjum Naeem Ansari, Meteb Alfoheidi, Ahmed Absi, Turki Alfayea, Eman Youssif, Ayman Alhejazi, Mansour Alodhaib","doi":"10.1080/17512433.2025.2492063","DOIUrl":"https://doi.org/10.1080/17512433.2025.2492063","url":null,"abstract":"Introduction: Biosimilars have the potential to offer cost savings with comparable efficacy and safety to innovator products and, thus, increase access to treatment for more patients. However, there were significant challenges in the acceptance of oncology biosimilars in our organization in the beginning which we addressed by implementing practical strategies described in the paper.Areas covered: While much of the published literature places an emphasis on the pharmacoeconomic impact of biosimilars, this paper is a novel addition to the literature because it provides practical experience and detailed processes for the formulary adoption and implementation of oncology biosimilars along with a focus on their pharmacoeconomic impact, education of oncology healthcare professionals, pharmacovigilance, and integration into the electronic health record. A narrative literature review was conducted to identify the existing evidence on biosimilar adoption and implementation in the oncology setting.Expert opinion: Healthcare organizations must establish a consistent method for assessing and adopting oncology biosimilars to increase efficiency and coordination among the many team members responsible for their introduction into clinical practice. Conducting medication use evaluations and real-world evidence studies of biosimilars can help in building trust among healthcare professionals and patients in biosimilars.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1-9"},"PeriodicalIF":3.6,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Detrimental impact of gastric acid suppressants on vascular endothelial growth factor receptor tyrosine kinase inhibitors efficacy: evidence from a systematic review and meta-analysis. 胃酸抑制剂对血管内皮生长因子受体酪氨酸激酶抑制剂疗效的不利影响：来自系统评价和荟萃分析的证据。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2025-04-21 DOI: 10.1080/17512433.2025.2492062

Jiefeng Luo, Qiong Du, Jiyong Liu

{"title":"Detrimental impact of gastric acid suppressants on vascular endothelial growth factor receptor tyrosine kinase inhibitors efficacy: evidence from a systematic review and meta-analysis.","authors":"Jiefeng Luo, Qiong Du, Jiyong Liu","doi":"10.1080/17512433.2025.2492062","DOIUrl":"https://doi.org/10.1080/17512433.2025.2492062","url":null,"abstract":"Background: This meta-analysis evaluated the prevalence of gastric acid suppressants (GASs) in patients receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) and explored drug-drug interactions (DDIs).Methods: PubMed, Embase, and Cochrane Library were searched upto 20 October 2024. Studies comparing VEGFR-TKIs monotherapy versus VEGFR-TKIs with GASs, reporting pharmacodynamic (PD), pharmacokinetic (PK), or adverse events (AEs), were analyzed using random-effects models. Subgroups included cancer types and VEGFR-TKI types.Results: 24 studies comprising 6,406 patients were included. The prevalence of GASs use in VEGFR-TKIs users was 40% (95% CI 31-50%). GASs significantly impaired survival, increasing mortality risk by 29% (OS HR 1.29,95% CI 1.14-1.45) and progression risk by 31% (PFS HR 1.31, 95% CI 1.06-1.61). PK analyses revealed clinically meaningful exposure reductions (AUC0-24GMR 0.78, 90% CI 0.65-0.94; Cmax GMR 0.80, 90% CI 0.70-0.91). AE incidence (except vomiting) did not differ between groups.Conclusion: GASs may reduce the efficacy of most types of VEGFR-TKIs by decreasing their bioavailability, thereby having a detrimental effect on patient survival outcomes. It is recommended to give priority to H2 receptor antagonists (H2RAs) and monitor blood drug concentrations to optimize efficacy.Protocol registration: www.crd.york.ac.uk/prospero identifier CRD42024597729.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1-16"},"PeriodicalIF":3.6,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A profile of safety and efficacy of fezolinetant for the treatment of menopausal vasomotor symptoms. 非唑啉奈坦治疗绝经期血管舒缩症状的安全性和有效性。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2025-04-21 DOI: 10.1080/17512433.2025.2495951

Laura Cucinella, Chiara Cassani, Sara Tedeschi, Stefano Memoli, Ellis Martini, Rossella E Nappi

{"title":"A profile of safety and efficacy of fezolinetant for the treatment of menopausal vasomotor symptoms.","authors":"Laura Cucinella, Chiara Cassani, Sara Tedeschi, Stefano Memoli, Ellis Martini, Rossella E Nappi","doi":"10.1080/17512433.2025.2495951","DOIUrl":"https://doi.org/10.1080/17512433.2025.2495951","url":null,"abstract":"Introduction: Fezolinetant is a first-in-class non-hormonal pharmacological treatment recently approved for moderate-to-severe vasomotor symptoms (VMS) associated with menopause. Its mechanism of action selectively targets the pathophysiology of VMS at hypothalamic level, antagonizing binding of neurokinin B, overexpressed in estrogen deprived menopausal women, to the neurokinin 3 receptor (NK3R) in the thermoregulatory center.Areas covered: Fezolinetant reduced VMS frequency and severity in phase 3 randomized placebo-controlled trials in healthy menopausal women (SKYLIGHT 1 and 2) and in women unsuitable for menopause hormone therapy (MHT) (DAYLIGHT). The effect on VMS positively translated into improvements in menopause-specific quality of life, as well as sleep disturbances and impairment. Safety data were reassuring across studies, especially 52-weeks safety trials (SKYLIGHT 4 and MOONLIGHT 3).Expert opinion: Fezolinetant represents a highly anticipated innovation, offering the possibility to bridge the therapeutic gap for many women who cannot or do not wish to use MHT. While the potential application of fezolinetant in some clinical settings will add substantial value to the management of VMS, some research gaps need to be addressed in order to provide meaningful insight into the benefit-risk profile that ultimately will improve counseling and prescription tailoring in symptomatic menopausal women.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1-12"},"PeriodicalIF":3.6,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143991604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of the augmentation with quetiapine or olanzapine on the metabolism of duloxetine: a retrospective analysis. 喹硫平或奥氮平对度洛西汀代谢的影响：回顾性分析。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2025-04-04 DOI: 10.1080/17512433.2025.2486998

Nele Römer, Arnim Johannes Gaebler, Irene Neuner, Ekkehard Haen, Christoph Hiemke, Georgios Schoretsanitis, Michael Paulzen

{"title":"Effects of the augmentation with quetiapine or olanzapine on the metabolism of duloxetine: a retrospective analysis.","authors":"Nele Römer, Arnim Johannes Gaebler, Irene Neuner, Ekkehard Haen, Christoph Hiemke, Georgios Schoretsanitis, Michael Paulzen","doi":"10.1080/17512433.2025.2486998","DOIUrl":"10.1080/17512433.2025.2486998","url":null,"abstract":"Background: In antidepressant augmentation strategies, olanzapine or quetiapine are often concomitantly administered to duloxetine. The use of the same enzymes for the degradation of the drugs may lead to clinically relevant drug-drug-interactions, DDIs. So far, DDIs between olanzapine or quetiapine and duloxetine have only been studied in rats or in small numbers of patients.Methods: Out of a large therapeutic drug monitoring (TDM) database of duloxetine concentrations, three matched study groups were considered to investigate potential DDIs: a group of patients co-medicated with olanzapine (n = 81), a group co-medicated with quetiapine (n = 105) and a control group receiving only duloxetine (n = 105).Results: Neither in the olanzapine group, nor in the quetiapine group, duloxetine plasma concentrations or dose-adjusted plasma concentrations differed significantly from the control group (p = 0.6759; p = 0.5841). The proportion of patients within the so-called therapeutic reference range was similar in all three groups (p = 0.635). However, smokers showed by 30% lower duloxetine plasma concentrations (p = 0.0179) and 32.5% lower dose-adjusted concentrations (p = 0.0003) compared to nonsmokers.Conclusion: Our findings indicate that the combination of duloxetine and olanzapine or quetiapine is - from a pharmacokinetic view - a safe treatment option. TDM should be applied in case of co-medications to enhance therapeutic effectiveness and patients' safety.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1-7"},"PeriodicalIF":3.6,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of COVID-19 pandemic on the prescribing pattern of oral anticoagulants in the English primary care setting: a population-based segmented interrupted time series analysis of over 53 million individuals. COVID-19大流行对英国初级保健机构口服抗凝剂处方模式的影响：对5300多万人进行的基于人群的分段中断时间序列分析

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2025-04-01 Epub Date: 2025-03-04 DOI: 10.1080/17512433.2025.2473613

Amanj Kurdi, Abdulaziz Albutti, Omeed Darweesh, Karwan M Amen, Kirmanj Baker, Hardee Karwi, Brian Godman

{"title":"Impact of COVID-19 pandemic on the prescribing pattern of oral anticoagulants in the English primary care setting: a population-based segmented interrupted time series analysis of over 53 million individuals.","authors":"Amanj Kurdi, Abdulaziz Albutti, Omeed Darweesh, Karwan M Amen, Kirmanj Baker, Hardee Karwi, Brian Godman","doi":"10.1080/17512433.2025.2473613","DOIUrl":"10.1080/17512433.2025.2473613","url":null,"abstract":"Background: The COVID-19 pandemic disrupted healthcare delivery, impacting oral anticoagulants (OAC) prescribing due to increased thromboembolic risks, Vaccine-induced immune thrombotic thrombocytopenia, and guidelines favoring Direct Oral Anticoagulants (DOACs) over warfarin. Previous studies were limited to short-term analyses.Research design and methods: A segmented interrupted time series analysis was conducted using the English primary care Prescription Cost Analysis data from March/2018-March/2024 to assess the impact of the first and second COVID-19 lockdowns in March and November 2020, respectively. Trends in OAC utilisation were measured using number of items per 1,000 inhabitants (NIT) and defined daily dose per 1,000 inhabitants per day (DTD).Results: Overall, oral anticoagulants prescribing increased significantly. Pre-pandemic, both NIT (β1: 0.09; 95%CI: 0.02, 0.16) and DTD (β1:0.13; 95%CI: 0.09, 0.16) showed positive trends. Post-first lockdown, DTD slope declined significantly (β3:-0.22; 95%CI: -0.42, -0.03). Post-second lockdown, DTD rose in both immediate level (β4:1.39; 95%CI: 0.34, 2.45) and slope (β5: 0.20; 95%CI: 0.0015, 0.39). Warfarin usage declined initially but rebounded, while DOACs, particularly apixaban, increased substantially (β4:0.96; 95%CI: 0.11, 1.81).Conclusions: The COVID-19 pandemic significantly impacted oral anticoagulant prescribing patterns in England. While DOAC utilisation continued to rise, warfarin use declined significantly post-first lockdown but rebounded after the second lockdown.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"237-246"},"PeriodicalIF":3.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143531576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Scoping review of the availability and uptake of disease modifying therapies in children and adolescents with multiple sclerosis. 儿童和青少年多发性硬化症疾病修饰疗法的可用性和吸收的范围综述。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2025-04-01 Epub Date: 2025-03-24 DOI: 10.1080/17512433.2025.2481868

Lauren Strasser, Beyza Ciftci, Joley Johnstone, Jessie Cunningham, Helen Tremlett, E Ann Yeh

{"title":"Scoping review of the availability and uptake of disease modifying therapies in children and adolescents with multiple sclerosis.","authors":"Lauren Strasser, Beyza Ciftci, Joley Johnstone, Jessie Cunningham, Helen Tremlett, E Ann Yeh","doi":"10.1080/17512433.2025.2481868","DOIUrl":"10.1080/17512433.2025.2481868","url":null,"abstract":"Introduction: Approximately 10% of individuals with multiple sclerosis (MS) have pediatric-onset (<18-years-old). Pediatric-specific barriers to accessing disease modifying therapies (DMT) exist. Issues include few pediatric-based randomized controlled trials (RCT), often required for formal regulatory approval, and resultant challenges with cost/coverage. This review assessed real-world DMT uptake in pediatric-MS to better understand potential barriers.Areas covered: We performed a scoping review of observational studies examining DMTs in patients with pediatric-MS published between 07/1993 and 06/2024. PRISMA guidelines were used. Databases searched included: Cochrane Library, Ovid MEDLINE/Embase, Scopus, and Web of Science. Studies must include >10 DMT exposed pediatric-MS patients with full-text available in English. RCTs/pharmaceutical-industry funded studies were excluded. Of 2114 abstracts screened, 88 studies were included. A total of 21,591 patients (13,411 females) were included. DMTs were used in 68.7% (n = 14,833). Most studies were from Europe (53.4%), North America (22.7%), or the Middle East (10%). Regional variabilities were found in DMT uptake between continents. Only 13 (14.8%) studies included information on DMT funding source.Expert opinion: Pediatric-MS patients showed low DMT uptake with variability in DMT use based on region. Limited data was found regarding specific barriers to DMT access. Further research is needed to better understand regional barriers to access.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"197-210"},"PeriodicalIF":3.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can we optimize the use of renin-angiotensin-system inhibitors in patients with chronic kidney disease? 我们能否优化肾素-血管紧张素系统抑制剂在慢性肾病患者中的应用？

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2025-04-01 Epub Date: 2025-02-19 DOI: 10.1080/17512433.2025.2468954

Panagiotis I Georgianos, Christodoula Kourtidou, Konstantinos Leivaditis, Anastasios Kollias, Vassilios Liakopoulos

引用次数: 0

Efficacy and safety of dupilumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis. dupilumab治疗慢性鼻窦炎伴鼻息肉的疗效和安全性：一项系统综述和荟萃分析。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2025-04-01 Epub Date: 2025-02-22 DOI: 10.1080/17512433.2025.2468970

Linger Sim, Norasnieda Md Shukri, Najib Majdi Yaacob, Chenthilnathan Periasamy, Musat Gabriela Cornelia, Baharudin Abdullah

{"title":"Efficacy and safety of dupilumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis.","authors":"Linger Sim, Norasnieda Md Shukri, Najib Majdi Yaacob, Chenthilnathan Periasamy, Musat Gabriela Cornelia, Baharudin Abdullah","doi":"10.1080/17512433.2025.2468970","DOIUrl":"10.1080/17512433.2025.2468970","url":null,"abstract":"Introduction: Chronic rhinosinusitis with nasal polyps (CRSwNP) primarily displays type 2 inflammation, characterized by the activation of interleukin (IL)-4, IL-5, and IL-13 in the pathway. The purpose of this study is to determine the efficacy and safety of dupilumab (an IL-4 antagonist) in treating CRSwNP.Methods: A detailed search was performed in PubMed, Embase and the Cochrane Library databases. All published English-language randomized controlled trials (RCTs) that employed dupilumab to treat CRSwNP in adult patients (≥18 years old) were considered.Results: Three RCTs and 25 studies with 784 individuals were included. The use of dupilumab revealed improvement in polyp size (MD -1.80; 95% CI -2.25 to -1.36), Lund-Mackay score (MD -7.01, 95% CI -9.64 to -4.38), congestion (MD -0.86, 95% CI -0.99 to -0.73), smell (MD 10.83, 95% CI 9.59 to 12.08) and health-related quality of life (MD -19.61, 95% CI -22.53 to -16.69). Systemic corticosteroid use (RR 0.28, 95% CI 0.20-0.39) and revision surgery (RR 0.17, 95% CI 0.05-0.52) were reduced. Serious adverse events were reduced in dupilumab group (RR 0.47; 95% CI 0.29 to 0.76) with no change in risk of adverse events (RR 0.98, 95% CI 0.87 to 1.11).Conclusions: Dupilumab is effective with minimal adverse events.Protocol registration: www.crd.york.ac.uk/prospero identifier is CRD42023413004.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"211-224"},"PeriodicalIF":3.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0